The PRO2TECT CONVERSION Study will compare vadadust, an investigational (potential new) medication, to an existing, approved anemia medication, given by injection. The potential new medication is taken by mouth.
You may be able to take part in this study if you:
are 18 years of age or older
have chronic kidney disease (CKD) but you are not on dialysis
already take a medication such as Procrit (R), Eprex (R), Mircera (R), Neorecormon (R), Epogen (R), or Aranesp TM [darbepoetin alfa] for anemia
have not had an organ transplant and are not due to have a kidney transplant
Participation in the PRO2Tect - CONVERSION Study will last between 1.5 and 4 years and will require regular visits to the studycenter. The study medication (potential new medication and approved anemia medication) and allstudy-related assesments will be provided at no cost to you.
If you are interested in learning more about this study, please contact: